According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. “
Separately, Cowen and Company restated a buy rating on shares of Loxo Oncology in a report on Wednesday, July 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $29.60.
Loxo Oncology (NASDAQ:LOXO) traded down 2.42% during midday trading on Wednesday, reaching $22.95. The company’s stock had a trading volume of 26,559 shares. The firm has a 50-day moving average price of $26.52 and a 200 day moving average price of $25.44. Loxo Oncology has a 52-week low of $16.36 and a 52-week high of $35.00. The stock’s market capitalization is $497.19 million.
Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.14. Equities research analysts predict that Loxo Oncology will post ($2.83) EPS for the current fiscal year.
In other Loxo Oncology news, Director David P. Bonita sold 447,857 shares of Loxo Oncology stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $26.96, for a total value of $12,074,224.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Keith T. Flaherty sold 15,000 shares of Loxo Oncology stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $26.00, for a total transaction of $390,000.00. Following the completion of the sale, the director now owns 60,482 shares in the company, valued at $1,572,532. The disclosure for this sale can be found here. 44.40% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Loxo Oncology by 7.4% in the first quarter. State Street Corp now owns 133,074 shares of the biopharmaceutical company’s stock worth $3,638,000 after buying an additional 9,142 shares during the period. UBS Asset Management Americas Inc. purchased a new position in shares of Loxo Oncology during the first quarter worth approximately $2,197,000. Geode Capital Management LLC increased its position in shares of Loxo Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 57,068 shares of the biopharmaceutical company’s stock worth $1,560,000 after buying an additional 2,126 shares during the period. Wellington Management Group LLP purchased a new position in shares of Loxo Oncology during the first quarter worth approximately $13,518,000. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Loxo Oncology by 40.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 700,000 shares of the biopharmaceutical company’s stock worth $19,138,000 after buying an additional 200,000 shares during the period. Hedge funds and other institutional investors own 95.46% of the company’s stock.
About Loxo Oncology
Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.